U.K. agency recommends Sucampo drug

Sucampo Pharmaceuticals Inc.,  of Bethesda, a global biopharmaceutical company, announced that the United Kingdom’s National Institute of Health and Care Excellence has issued a guidance recommending the use of Sucampo’s Amitiza (lubiprostone) in the treatment of chronic idiopathic constipation and associated symptoms in adults who have failed laxatives. The guidance recommends Amitiza as an option for adults for whom invasive treatment for constipation is being considered.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>


Scroll To Top